GeoVax Labs Inc (GOVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeoVax Labs Inc (GOVX) has a cash flow conversion efficiency ratio of -1.266x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.21 Million) by net assets ($4.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GeoVax Labs Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how GeoVax Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GeoVax Labs Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
GeoVax Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeoVax Labs Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UNITED OIL+GAS PLC LS-01
F:1UO
|
N/A |
|
GECI International SA
PA:ALGEC
|
-0.006x |
|
Avingtrans Plc
LSE:AVG
|
0.057x |
|
WestKam Gold Corp
V:WKG
|
0.023x |
|
Galore Resources Inc
V:GRI
|
-0.036x |
|
Harris Technology Group Ltd
AU:HT8
|
-0.192x |
|
Silver Predator Corp
V:SPD
|
-0.013x |
|
Dolfines SAS
PA:ALDOL
|
0.141x |
Annual Cash Flow Conversion Efficiency for GeoVax Labs Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of GeoVax Labs Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see GOVX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.05 Million | $-24.68 Million | -4.888x | -11.90% |
| 2023-12-31 | $5.76 Million | $-25.17 Million | -4.368x | -510.53% |
| 2022-12-31 | $26.60 Million | $-19.03 Million | -0.715x | +72.13% |
| 2021-12-31 | $4.36 Million | $-11.20 Million | -2.567x | -792.97% |
| 2020-12-31 | $9.57 Million | $-2.75 Million | -0.287x | -132.36% |
| 2019-12-31 | $-1.57 Million | $-1.40 Million | 0.888x | -41.17% |
| 2018-12-31 | $-1.02 Million | $-1.54 Million | 1.510x | -71.29% |
| 2017-12-31 | $-321.06K | $-1.69 Million | 5.259x | +164.96% |
| 2016-12-31 | $240.37K | $-1.95 Million | -8.096x | -260.52% |
| 2015-12-31 | $1.20 Million | $-2.71 Million | -2.246x | -14.40% |
| 2014-12-31 | $1.15 Million | $-2.25 Million | -1.963x | -192.77% |
| 2013-12-31 | $2.53 Million | $-1.69 Million | -0.671x | +68.39% |
| 2012-12-31 | $1.15 Million | $-2.44 Million | -2.121x | -391.54% |
| 2011-12-31 | $703.61K | $-303.62K | -0.432x | +60.52% |
| 2010-12-31 | $1.84 Million | $-2.01 Million | -1.093x | -187.18% |
| 2009-12-31 | $3.74 Million | $-1.43 Million | -0.381x | +56.44% |
| 2008-12-31 | $2.71 Million | $-2.37 Million | -0.874x | +29.15% |
| 2007-12-31 | $2.65 Million | $-3.27 Million | -1.233x | -104.63% |
| 2006-12-31 | $2.20 Million | $-1.33 Million | -0.603x | -341.49% |
| 2005-12-31 | $-5.72 Million | $-1.43 Million | 0.250x | -0.01% |
| 2004-12-31 | $-4.95 Million | $-1.23 Million | 0.250x | +430.50% |
| 2003-12-31 | $-3.82 Million | $288.31K | -0.076x | +96.33% |
| 2001-12-31 | $2.05 Million | $-4.21 Million | -2.056x | -241.90% |
| 2000-12-31 | $10.52 Million | $-6.33 Million | -0.601x | +92.55% |
| 1999-12-31 | $552.34K | $-4.46 Million | -8.070x | -335.13% |
| 1998-12-31 | $2.89 Million | $-5.35 Million | -1.855x | -330.19% |
| 1997-12-31 | $5.68 Million | $-2.45 Million | -0.431x | -14.43% |
| 1996-12-31 | $3.09 Million | $-1.17 Million | -0.377x | -- |
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more